- Home
- CANF vs NWBI Comparison
CANF vs NWBI Comparison
Compare CANF & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NWBI
- Stock Information
- Founded
- CANF 1994
- NWBI 1896
- Country
- CANF Israel
- NWBI United States
- Employees
- CANF N/A
- NWBI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NWBI Major Banks
- Sector
- CANF Health Care
- NWBI Finance
- Exchange
- CANF Nasdaq
- NWBI Nasdaq
- Market Cap
- CANF 7.9M
- NWBI N/A
- IPO Year
- CANF N/A
- NWBI N/A
- Fundamental
- Price
- CANF $1.12
- NWBI $12.52
- Analyst Decision
- CANF Strong Buy
- NWBI Hold
- Analyst Count
- CANF 2
- NWBI 1
- Target Price
- CANF $14.00
- NWBI $15.00
- AVG Volume (30 Days)
- CANF 444.9K
- NWBI 932.3K
- Earning Date
- CANF 05-20-2025
- NWBI 04-28-2025
- Dividend Yield
- CANF N/A
- NWBI 6.37%
- EPS Growth
- CANF N/A
- NWBI N/A
- EPS
- CANF N/A
- NWBI 0.90
- Revenue
- CANF $674,000.00
- NWBI $518,578,999.00
- Revenue This Year
- CANF $461.72
- NWBI $1.67
- Revenue Next Year
- CANF N/A
- NWBI $15.93
- P/E Ratio
- CANF N/A
- NWBI $13.97
- Revenue Growth
- CANF N/A
- NWBI N/A
- 52 Week Low
- CANF $1.02
- NWBI $10.49
- 52 Week High
- CANF $4.69
- NWBI $15.42
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- NWBI 62.55
- Support Level
- CANF $1.02
- NWBI $12.41
- Resistance Level
- CANF $1.20
- NWBI $12.67
- Average True Range (ATR)
- CANF 0.06
- NWBI 0.27
- MACD
- CANF 0.01
- NWBI 0.11
- Stochastic Oscillator
- CANF 41.30
- NWBI 86.71
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).